earnings
confidence high
sentiment neutral
materiality 0.75
Charles River Q3 revenue $1.01B (-1.6% YoY); non-GAAP EPS $2.59 beats prior outlook; narrows FY guidance
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
2024-Q3 EPS reported
$4.37
revenue$3,047,440,000
- Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.
- DSA segment organic revenue fell 7.4%; Manufacturing organic revenue grew 11.8%.
- Board approved $1B stock repurchase; $100.7M spent in Q3, $899.3M remaining.
- FY 2024 guidance narrowed: reported revenue (3%)-(2%); non-GAAP EPS raised to $10.10-$10.30.
- CEO cites stable demand indicators and biotech funding improvement; restructuring actions continue.